-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2649 Predictors and Timing of Venous Thromboembolism in Lung Cancer

Program: Oral and Poster Abstracts
Session: 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Research, Bleeding and Clotting, adult, Clinical Practice (Health Services and Quality), Clinical Research, Diseases, real-world evidence, thrombotic disorders, Study Population, Human
Sunday, December 10, 2023, 6:00 PM-8:00 PM

Thomas Plate IV, MD1, Asaad Trabolsi, MD1, Rachel S. Kronenfeld, MD2, Leticia E. Campoverde, MD3, Dan Morgenstern Kaplan, MD, MSc4*, Alyssa Mercadel, MD5*, Michael Caballero, PhD6*, Wei Zhao, MD, MS7* and Gerald A. Soff, MD8

1Sylvester Comprehensive Cancer Center, University of Miami/ Jackson Memorial Hospital, Miami, FL
2Division of Pediatric Hematology/Oncology, University of Miami/Jackson Memorial Hospital, Miami, FL
3Internal Medicine Residency program, Department of Medicine, University of Miami/ Jackson Memorial Hospital, Miami, FL
4Internal Medicine Residency program, division of internal medicine, Department of Medicine, University of Miami/ Jackson Memorial Hospital, Miami
5Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Miami Leonard M. Miller School of Medicine, Miami
6Data Science and Engineering, UHealth Information Technology, University of Miami, Miami, FL
7Sylvester Comprehensive Cancer Center, Department of Public Health Sciences, Miami
8Sylvester Comprehensive Cancer Center, University of Miami Miller School of medicine, Miami, FL


Venous thromboembolism (VTE) is a common complication in lung cancer, but its risk factors and incidence have not been fully characterized. While prophylactic anticoagulation is recommended for some patient with cancer to prevent VTE, the thrombosis-risk prediction Khorana score considers lung cancer intermediate risk for development of VTE and combines all subtypes of lung cancer into a single entity. There are also limited data on the impact of therapy-type on VTE risk in patients with lung cancer. This study aimed to identify the incidence of VTE and its associated risk factors in patients with lung cancer at our university cancer center.


Using data from our tumor registry, we identified patients diagnosed with lung cancer between 2018 and 2022 who received first therapy beyond surgery alone after date of first contact. Using automated text search from our electronic medical record (EPIC®) combined with natural language processing review, VTE events were identified from 90-days before and up to one year(y) after initiation of systemic therapy. VTE events, including lower extremity deep vein thrombosis (DVT) or pulmonary embolism (PE), were captured by physician investigators, with final, secondary adjudication by one of us (GAS). We report time to event analysis and survival analysis using Kaplan-Meier curve. The study was censored at one year. Univariate and multivariate analyses were performed using COX-regression model. We evaluated the effect of lung cancer subtype, stage, age, sex, race, ethnicity, white blood cell count, hemoglobin, and platelet count.


A total of 635 lung cancer patients were included in the study with a median age of 65 years. The median white blood cell count (WBC) was 8.8 × 109/L, median hemoglobin (Hgb) was 12.7 g/dL, and platelets (Plt) was 284 × 109/L. Other patient characteristics can be seen in Table 1.

The overall 12-month incidence of VTE (lower extremity DVT and/or PE) was 10.1% (n=64). Of the 64 VTE events, 20 were identified before the start of therapy. Univariate analysis revealed that age <60 and WBC >= 11 were associated with a higher risk of VTE (p<0.05), which remained significant after multivariate analysis including age, stage, WBC, and surgery.

There was a trend towards a higher risk of VTE in patients receiving chemoimmunotherapy, compared with chemotherapy alone, (HR 1.22), although this trend did not reach significance. Targeted therapy was associated with a lower trend (HR = 0.89), but that also was not significant.

The median overall survival was 18 months. Univariate analysis showed that VTE was associated with an increased risk of death (HR 2.05, p<0.001). Other parameters associated with reduced Overall Survival (OS) were age >=60, male sex, stage III-IV, WBC, Hgb, and Plt. After multivariate analysis considering age, sex, stage, lung cancer histology, Hgb, Plt, WBC, surgery, therapy type, and VTE, age >=60, stage III-IV, WBC >=11, Hgb <10, and VTE remained significant predictors of death.


In a retrospective study of more than 600 patients with lung cancer, there was a significant risk of VTE. Every subgroup of patients analyzed in this study retained a high risk of VTE after multivariate analysis. The only hematologic parameter from the Khorana score significantly associated with VTE after multivariate analysis was WBC. WBC and Hgb were associated with increased risk of death. Age <= 60 was associated with increased risk of VTE, while age >60 was associated with increased mortality. There was a trend towards a higher risk of VTE in patients receiving chemoimmunotherapy compared with chemotherapy alone. There were too few immunotherapy-only patients to allow for any interpretation. The development of thrombosis was associated with a significantly decreased overall survival, although we do not have data on the potential contribution of VTE to death. These findings were derived from a single-center data set, and further validation using independent data sets is warranted. If confirmed, a prospective study re-evaluating the risk of VTE and benefits of prophylactic anticoagulation specifically in contemporary patients with lung cancer receiving systemic therapy regardless of histology, treatment, or other factors described here may be indicated. Our findings do not support limiting any such study to any specific sub-group of patients with lung cancer.

Disclosures: Trabolsi: Johnson & Johnson: Current equity holder in publicly-traded company. Kronenfeld: Bayer Healthcare Pharmaceuticals: Research Funding. Caballero: Microsoft Corp: Current equity holder in publicly-traded company; Organon & Co: Current equity holder in publicly-traded company; Exact Sciences Corp: Current equity holder in publicly-traded company; Merck And Co Inc: Current equity holder in publicly-traded company. Soff: Anthos Therapeutics: Research Funding; Sanofi: Consultancy.

*signifies non-member of ASH